Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 117

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 117
---
 the case may be. We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of the Company and in connection with the preparation, negotiation and execution of the Purchase Agreement. See “The Committed Equity Financing” for more information.

| 75 |

We also have agreed to indemnify
the Selling Shareholder and certain other persons against certain liabilities in connection with the offering of our Depositary Shares
offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities. The Selling Shareholder has agreed to indemnify us against liabilities under the Securities
Act that may arise from certain written information furnished to us by the Selling Shareholder specifically for use in this prospectus
or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised
that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

We estimate that the total
expenses, including the Commitment Fee, for the offering will be approximately $1.7 million.

The Selling Shareholder has
represented to us that at no time prior to the date of the Purchase Agreement has the Selling Shareholder or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule
200 of Regulation SHO of the Exchange Act) of our Depositary Shares or any hedging transaction, which establishes a net short position
with respect to our Depositary Shares. The Selling Shareholder has agreed that during the term of the Purchase Agreement, neither the
Selling Shareholder, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the
foregoing transactions.

We have advised the Selling
Shareholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Shareholder, any affiliated purchasers, and any broker-dealer or other person who participates in the